Movement Alert｜DUALITYBIO-B Falls 5.02% in Regular Trading, Trading at HK$204.2

Market Focus09-24

On September 24, DUALITYBIO-B fell 5.02% in regular trading, trading at HK$204.2 per share, with turnover of HK$30.27 million.

Within the Biotechnology sector where DUALITYBIO-B belongs, the overall sector trended lower. Among individual stocks, AKESO down 3.64%, INNOVENT BIO down 3.63%, BEONE MEDICINES down 1.56%, REMEGEN down 5.84%, 3SBIO down 3.76%.

DUALITYBIO-B is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugate (ADC) therapies for cancer and autoimmune diseases. Its key pipeline candidates include DB-1303/BNT323, DB-1311/BNT324, and DB-1310, covering indications such as endometrial cancer, breast cancer, and small cell lung cancer. The company recently entered a global collaboration with Genentech to co-develop next-generation ADCs based on its proprietary DUPAC payload platform, receiving a US$45 million upfront payment with potential milestone payments exceeding US$1 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160035485?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160035485","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Falls 5.02% in Regular Trading, Trading at HK$204.2","media":"Market Focus","content":"<p><p>On September 24, DUALITYBIO-B fell 5.02% in regular trading, trading at HK$204.2 per share, with turnover of HK$30.27 million.</p><p>Within the Biotechnology sector where DUALITYBIO-B belongs, the overall sector trended lower. Among individual stocks, AKESO down 3.64%, INNOVENT BIO down 3.63%, BEONE MEDICINES down 1.56%, REMEGEN down 5.84%, 3SBIO down 3.76%.</p><p>DUALITYBIO-B is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugate (ADC) therapies for cancer and autoimmune diseases. Its key pipeline candidates include DB-1303/BNT323, DB-1311/BNT324, and DB-1310, covering indications such as endometrial cancer, breast cancer, and small cell lung cancer. The company recently entered a global collaboration with Genentech to co-develop next-generation ADCs based on its proprietary DUPAC payload platform, receiving a US$45 million upfront payment with potential milestone payments exceeding US$1 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Falls 5.02% in Regular Trading, Trading at HK$204.2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Falls 5.02% in Regular Trading, Trading at HK$204.2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, DUALITYBIO-B fell 5.02% in regular trading, trading at HK$204.2 per share, with turnover of HK$30.27 million.</p><p>Within the Biotechnology sector where DUALITYBIO-B belongs, the overall sector trended lower. Among individual stocks, AKESO down 3.64%, INNOVENT BIO down 3.63%, BEONE MEDICINES down 1.56%, REMEGEN down 5.84%, 3SBIO down 3.76%.</p><p>DUALITYBIO-B is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugate (ADC) therapies for cancer and autoimmune diseases. Its key pipeline candidates include DB-1303/BNT323, DB-1311/BNT324, and DB-1310, covering indications such as endometrial cancer, breast cancer, and small cell lung cancer. The company recently entered a global collaboration with Genentech to co-develop next-generation ADCs based on its proprietary DUPAC payload platform, receiving a US$45 million upfront payment with potential milestone payments exceeding US$1 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1160035485","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160035485","pubTimestamp":1790215840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, DUALITYBIO-B fell 5.02% in regular trading, trading at HK$204.2 per share, with turnover of HK$30.27 million.Within the Biotechnology sector where DUALITYBIO-B belongs, the overall...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DUALITYBIO-B常规交易跌5.02%，报204.2港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On September 24, DUALITYBIO-B fell 5.02% in regular trading, trading at HK$204.2 per share, with turnover of HK$30.27 million.Within the Biotechnology sector where DUALITYBIO-B belongs, the overall sector trended lower. Among individual stocks, AKESO down 3.64%, INNOVENT BIO down 3.63%, BEONE MEDICINES down 1.56%, REMEGEN down 5.84%, 3SBIO down 3.76%.DUALITYBIO-B is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugate (ADC) therapies for cancer and autoimmune diseases. Its key pipeline candidates include DB-1303/BNT323, DB-1311/BNT324, and DB-1310, covering indications such as endometrial cancer, breast cancer, and small cell lung cancer. The company recently entered a global collaboration with Genentech to co-develop next-generation ADCs based on its proprietary DUPAC payload platform, receiving a US$45 million upfront payment with potential milestone payments exceeding US$1 billion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160035485","isCrawlerRequest":true}